Meeting
2021 ASCO Annual Meeting
Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).
Authors
Yun Zhang
The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China
Yun Zhang , Jianming Xu , Jie Shen , Shanzhi Gu , Lihua Wu , Jian Wu , Guoliang Shao , Yanqiao Zhang , Li Xu , Tao Yin , Jingfeng Liu , Zhenggang Ren , Jianping Xiong , Xianhai Mao , Ling Zhang , Jiayin Yang , Lequn Li , Xiaoming Chen , Zhiming Wang , Quanren Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT03463876
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4076)
DOI
10.1200/JCO.2021.39.15_suppl.4076
Abstract #
4076
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.
First Author: Li Jingjing
Poster
2022 ASCO Annual Meeting
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
First Author: Huaying Wang